Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at UBS Group

UBS Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to a strong-buy rating in a report published on Wednesday,Zacks reports.

Several other equities analysts have also issued reports on ALNY. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Truist Financial dropped their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Needham & Company LLC reduced their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Oppenheimer reduced their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Finally, Bank of America decreased their target price on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $364.95.

Alnylam Pharmaceuticals Trading Down 0.9%

NASDAQ ALNY traded down $2.20 during trading on Wednesday, reaching $231.83. 1,404,802 shares of the stock traded hands, compared to its average volume of 1,301,571. The firm has a market cap of $31.02 billion, a price-to-earnings ratio of 43.09 and a beta of 0.28. The stock’s 50-day moving average price is $239.35 and its 200 day moving average price is $274.34. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a fifty-two week low of $197.81 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business’s quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.51) earnings per share. Analysts predict that Alnylam Pharmaceuticals will post 6.68 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $25,000. Toth Financial Advisory Corp acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. SHP Wealth Management bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $43,000. Keating Financial Advisory Services Inc. bought a new position in Alnylam Pharmaceuticals during the 2nd quarter worth about $42,000. Finally, Burkett Financial Services LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth about $37,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.